What is NDC 0024-0674?

0024-0674 is the product NDC for Sarclisa Escena (isatuximab-irfc), Isatuximab 140 mg/mL injection, solution, listed with the FDA by Sanofi-Aventis U.S. LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Sarclisa Escena (Isatuximab-irfc).

Sanofi-Aventis U.S. LLC, NDC labeler code 0024. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Sarclisa Escena?

None: this is the only finished product listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Sarclisa Escena NDC 0024-0674 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)0024-0674Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00024-0674Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0024-0674-01	0002406740100024067401	1 VIAL in 1 CARTON (0024-0674-01) / 10 mL in 1 VIALMarketed from Jul 9, 2026

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Sarclisa Escena
Generic name (nonproprietary): isatuximab-irfc
Active ingredients: Isatuximab — 140 mg/mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Sanofi-Aventis U.S. LLCNDC labeler code 0024
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761445
Marketing start: Jul 9, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Monoclonal (Chemical structure)CD38-directed Antibody Interactions (Mechanism)
Identifiers: Product ID 0024-0674_564889eb-80a7-336a-e063-6294a90a30c8SPL ID 564889eb-80a7-336a-e063-6294a90a30c8SPL set ID 07730e8c-1340-4d30-8d71-e20f850db8daRxCUI 2747132, 2747135UNII R30772KCU0
Pharmacologic class: CD38-directed Cytolytic Antibody

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N400024067401 followed by a unit qualifier and the quantity

Package 00024-0674-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 10, 2026.

Indications (excerpt from the label)

SARCLISA ESCENA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 1 prior line of therapy including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT). SARCLISA ESCENA is a CD38-directed cytolytic antibody indicated: in combi…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 0024-0674

What is NDC 0024-0674?: 0024-0674 is the product NDC for Sarclisa Escena (isatuximab-irfc), Isatuximab 140 mg/mL injection, solution, listed with the FDA by Sanofi-Aventis U.S. LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Sarclisa Escena (Isatuximab-irfc).
What is the active ingredient?: Isatuximab.
Who is the labeler?: Sanofi-Aventis U.S. LLC, NDC labeler code 0024. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Sarclisa Escena?: None: this is the only finished product listed under this name.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Sarclisa Escena (Isatuximab-irfc) NDC 0024-0674